Purpose of the Report

The *Dialysis Facility Report (DFR) for FY 2019* is provided as a resource for characterizing selected aspects of clinical experience at this facility relative to other caregivers in this state, ESRD Network, and across the United States. Since these data could be useful in quality improvement and assurance activities, each state's surveying agency may utilize this report as a resource during the FY 2019 survey and certification process.

This report has been prepared for this facility by the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) with funding from the Centers for Medicare & Medicaid Services (CMS) and is based primarily on data reported in CROWNWeb, Medicare claims and data collected for CMS. It is the twenty-third in a series of annual reports. This is one of 7,346 reports that have been distributed to ESRD providers in the U.S.

This DFR includes data specific to CCN(s): 502500

Overview: This report includes summaries of patient characteristics, treatment patterns, and patient outcomes for chronic dialysis patients who were treated in this facility between January 2014 and December 2017. Mortality, hospitalization, and transplantation statistics are reported for a three- or four-year period. Regional and national averages are included to allow for comparisons. Several of the summaries of patient mortality, hospitalization, and transplantation are adjusted to account for the characteristics of the patient mix at this facility, such as age, sex and diabetes as a cause of ESRD. Unless otherwise specified, data refer to hemodialysis (HD) and peritoneal dialysis (PD) patients combined.

Selected highlights from this report are given on pages 2 through 5. For a complete description of the methods used to calculate the statistics in this report, please see the *Guide to the Dialysis Facility Reports for FY 2019*. The *Guide* may be downloaded from the methodology section of the Dialysis Data website at www.DialysisData.org.

What's New This Year: As part of a continuing effort to improve the quality and relevance of this report for your facility, the following changes have been incorporated into the DFR for FY 2019. The Standardized Hospitalization Ratio (SHR) measures for days hospitalized and admissions were replaced by the new NQF-endorsed measures, which adjust for several prevalent comorbidities identified through Medicare claims. Hypercalcemia now includes patients with a missing three-month calcium average in both the numerator and denominator.

How to Submit Comments


Between July 15, 2018 and August 15, 2018, facilities may submit comments to their state surveyor or UM-KECC by visiting www.DialysisData.org, logging on to view their report, and clicking on the **Comments & Inquiries** tab. Questions or comments after the comment period is over may be submitted to us directly at DialysisData@umich.edu or 1-855-764-2885.


- (1) **State Surveyor:** Select "**DFR: Comments on DFR for State Surveyor**" from the drop down list to submit comments regarding this report for the state's surveyor(s). Any comments submitted will be appended and sent to the state's surveyor(s) in September 2018. Please do not include questions for UM-KECC using this option.
- (2) **UM-KECC:** Select "**DFR: Comments on DFR for UM-KECC**" to submit questions or suggestions to improve the DFR to UM-KECC. These comments will not be shared with CMS or your state surveyor.

Facility Highlights

Patient Characteristics (Tables 1 and 2):

- Among the 66 incident patients with Medical Evidence Forms (CMS-2728) indicating treatment at this facility during 2017:
 - 15% of these patients were not under the care of a nephrologist before starting dialysis, compared to 15% in your State, 16% in your Network, and 20% nationally.
 - 52% of these patients were informed of their transplant options, compared to 79% in your State, 81% in your Network, and 88% nationally.
- Among the patients treated at this facility on December 31, 2017, 20% were treated in a nursing home during the year, compared to 15% nationally.






Standardized Mortality Ratio (SMR) (Table 3):

• At this facility, the 2014-2017 SMR is 1.05, which is 5% more deaths than expected. Among all U.S. facilities, 61% of facilities had a four-year SMR (2014-2017) lower than 1.05. This difference is not statistically significant (p>=0.05), so this higher mortality could plausibly be just a chance occurrence. The 2014-2017 SMR of observed to expected deaths is 1.00 and 0.98 for your State and Network, respectively.

The markers show the values of the SMR for this facility, State, Network, and Nation. The bolded horizontal line shows the range of uncertainty due to random variation (95% confidence interval; significant if it does not cross the 1.0 reference line) Regional and national SMR are plotted above the dotted line to allow for comparisons to facility values.




• At this facility, the 2014-2016 first-year SMR of observed to expected deaths is 1.04, which is 4% more deaths than expected at this facility. Among all U.S. facilities, 58% of facilities had a first-year SMR lower than 1.04. This difference is not statistically significant (p>=0.05), so this higher mortality could plausibly be just a chance occurrence. The first-year SMR (2014-2016) of observed to expected deaths is 0.88 and 0.92 for your State and Network, respectively.

Hospitalizations and Readmissions (Table 4):

• The 2014-2017 SHR (Admissions) at this facility is 0.88, which is 12% fewer admissions hospitalized than expected. This difference is not statistically significant (p>=0.05), so this lower hospitalization could plausibly be just a chance occurrence. The 2014-2017 SHR (Admissions) for your State and Network is 0.90 and 0.87, respectively.

The markers show the values of the SHR (Admissions) for this facility, State, Network, and Nation. The bolded horizontal line shows the range of uncertainty due to random variation (95% confidence interval; significant if it does not cross the 1.0 reference line).


Regional and national SHR (Admissions) are plotted above the dotted line to allow for comparisons to facility values.




• The 2017 SRR at this facility is 0.97, which is 3% fewer readmissions than expected. This difference is not statistically significant (p>=0.05), so the lower number of readmissions could plausibly be just a chance occurrence. The 2017 SRR for your State and Network is 0.97 and 0.91, respectively.

Infection (Tables 4 and 11):

- The percentage of Medicare dialysis patients at this facility hospitalized with septicemia during 2014-2017 is 12.7%, compared to 11.8% in your State, 11.0% in your Network, and 11.2% nationally.
- The rate of PD catheter-related infection was 9.3 per 100 PD patient-months, compared to 4.0 in your State, 2.7 in your Network, and 2.9 nationally.





Transplantation (Table 5):

- Of the patients under age 70 treated at this facility during 2014-2017 who had not previously received a transplant, 10% were transplanted annually, while a rate of 4% would be expected for these patients.
- The 2014-2017 Standardized 1st Transplantation Ratio (STR) of observed to expected number of patients transplanted for this facility is 2.20, which is 120% higher than expected for this facility. This difference is statistically significant (p<0.05) and is unlikely to be due to random chance. The 2014-2017 STR for your State and Network is 1.27 and 1.24, respectively.


NKC - SEATTLE KIDNEY CENTER State: WA Network: 16 CCN: 502500


Transplant Waitlist (Table 6):


• Among the 165 dialysis patients under age 70 treated at this facility on December 31, 2017, 27% were on the kidney transplant waitlist, compared to 20% nationally. This difference is statistically significant (p<0.05) and is unlikely to be due to random chance. The percentage of patients on the kidney transplant waitlist on December 31, 2017, in your State and Network is 17% and 15%, respectively.

Influenza Vaccination (Table 7):

 Among the 160 Medicare dialysis patients treated at this facility on December 31, 2017, 71% were vaccinated between August 1 and December 31, 2017 compared to 72% nationally. This difference is not statistically significant (p>=0.05) and is plausibly due to random chance. The percentage of patients vaccinated in your State, Network, and US is 77%, 76%, and 72%, respectively.









Anemia Management (Table 8):

- Among the 106 ESA-treated HD patients in this facility included in the analysis in 2017, 15% had a hemoglobin value below 10 g/dL, compared to 13% in your State, 12% in your Network, and 17% nationally.
- Among the 36 ESA-treated PD patients in this facility included in the analysis in 2017, 14% had a hemoglobin value below 10 g/dL, compared to 21% in your State, 22% in your Network, and 26% nationally.

Dialysis Adequacy (Table 9):

- In 2017, 95% of eligible HD patient-months had a Kt/V >=1.2 reported, compared to 95% in your State, 96% in your Network, and 96% nationally.
- In 2017, 90% of eligible PD patient-months had a Kt/V >=1.7 reported, compared to 91% in your State, 92% in your Network, and 91% nationally.






Mineral Metabolism (Table 10):

- In 2017, 14% of eligible patient-months had a serum phosphorus value >7.0 mg/dL, compared to 16% in your State, 14% in your Network, and 13% nationally.
- In 2017, 1% of eligible patient-months had calcium uncorrected value >10.2 mg/dL, compared to 1% in your State, 1% in your Network, and 1% nationally.

Vascular Access (Table 11):

- At this facility in 2017, an average of 20% of incident patients had arteriovenous (AV) fistulae in place, compared to 26% in your State, 24% in your Network, and 17% nationally.
- Of the prevalent patients receiving hemodialysis treatment at this facility in 2017, 11% had a catheter which had been in place for at least 90 days as their only vascular access, compared to 10% in your State, 9% in your Network, and 11% nationally.






TABLE 1: Summaries for All Dialysis Patients Treated as of December 31st of Each Year 1, 2014-2017

			This I	acility		Region	nal Averages	¹ 2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
1a	Patients treated on 12/31 (n)	374	349	255	238	71.2	63.1	65.6
1b	Average age (years)	59.2	60.6	62.5	62.6	61.7	61.7	62.1
1c	Age (% of 1a; sums to 100%)							
	< 18	0.0	0.0	0.0	0.0	0.5	0.4	0.2
	18-64	59.6	58.5	53.3	55.0	53.0	52.7	53.1
	65+	40.4	41.5	46.7	45.0	46.6	46.9	46.7
1d	Female (% of 1a)	47.3	47.0	45.1	47.5	42.2	41.7	43.0
1e	Race (% of 1a; sums to 100%) *3							
	African American	28.6	27.5	30.2	31.5	11.5	8.3	34.8
	Asian/Pacific Islander	26.2	25.8	28.6	30.7	15.0	10.8	6.0
	Native American	0.3	0.6	0.8	0.8	1.6	3.0	1.2
	White	44.9	46.1	40.0	36.6	71.3	77.4	57.6
	Other/Unknown/Missing	0.0	0.0	0.4	0.4	0.6	0.5	0.4
1f	Ethnicity (% of 1a; sums to 100%)							
	Hispanic	8.8	8.3	7.5	7.6	12.7	12.4	18.5
	Non-Hispanic	90.9	91.4	92.2	92.0	86.9	87.2	81.2
	Unknown	0.3	0.3	0.4	0.4	0.4	0.4	0.3
1g	Primary Cause of ESRD (% of 1a; sums to 100%)							
	Diabetes	39.6	40.1	38.8	42.9	46.7	46.1	46.1
	Hypertension	16.3	15.8	17.3	18.9	17.9	17.5	29.7
	Glomerulonephritis	23.0	23.2	25.9	21.4	15.4	15.9	10.5
	Other/Unknown	20.9	20.6	16.9	15.5	19.4	19.7	12.9
	Missing	0.3	0.3	1.2	1.3	0.7	0.7	0.9
1h	Average duration of ESRD (years)	5.6	5.3	5.1	4.8	4.8	4.9	5.0
1i	Years since start of ESRD (% of 1a; sums to 100%)							
	< 1	12.8	14.0	18.8	14.7	18.0	17.6	15.6
	1-2	22.2	17.2	16.1	17.6	18.0	17.6	17.0
	2-3	12.8	17.8	12.5	15.1	13.7	13.8	13.9
	3-6	26.5	27.5	29.4	29.4	25.2	25.7	26.2
	6+	25.7	23.5	23.1	23.1	25.1	25.2	27.2
1j	Nursing home patients (% of 1a) *4	10.7	13.2	20.4	19.7	13.5	13.1	15.0
1k	Modality (% of 1a; sums to 100%)							
	In-center hemodialysis	34.2	43.6	50.6	51.7	85.1	83.2	87.6
	Home hemodialysis	14.4	9.5	7.5	6.3	2.4	2.2	1.8
	Continuous ambulatory peritoneal dialysis	6.4	6.3	7.8	4.6	1.2	1.8	1.4
	Continuous cycling peritoneal dialysis	37.7	33.8	22.4	27.7	10.4	12.1	8.8
	Other modality *5	7.2	6.9	11.8	9.7	0.8	0.6	0.4

n/a = not applicable

^[*1] See Guide, Section IV.

^[*2] Values are shown for the average facility.

^{[*3] &#}x27;Asian' includes Indian sub-continent. 'Native American' includes Alaskan Native. 'White' includes Middle Eastern and Arabian.

^[*4] Includes patients who were also treated by a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset.

^[*5] Other modality includes other dialysis, uncertain modality, and patients not on dialysis but still temporarily assigned to the facility (discontinued dialysis, recovered renal function, and lost to follow up).

TABLE 2: Characteristics of New Dialysis Patients *1 , 2014-2017 (Form CMS-2728)

			This F	acility		Region	nal Averages	¹ 2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
	Patient Characteristics							
2a	Total number of patients with forms (n)	47	71	70	66	19.6	17.3	16.7
2b	Average age (years [0-95]) *3	58.3	60.5	58.2	64.0	62.7	62.7	63.7
2c	Female (% of 2a)	38.3	45.1	48.6	33.3	38.8	39.9	42.3
2d	Race (% of 2a; sums to 100%)*4							
	African-American	31.9	19.7	32.9	22.7	8.2	5.8	26.1
	Asian/Pacific Islander	23.4	26.8	22.9	22.7	14.1	9.7	5.6
	Native American	2.1	0.0	0.0	3.0	1.7	2.8	0.9
	White	40.4	53.5	44.3	48.5	75.6	81.1	67.0
	Other/Unknown	2.1	0.0	0.0	3.0	0.4	0.6	0.3
2e	Hispanic (% of 2a)	4.3	4.2	7.1	6.1	9.4	8.9	15.0
2f	Primary cause of ESRD (% of 2a; sums to 100%)							
	Diabetes	44.7	39.4	42.9	48.5	50.2	50.8	49.0
	Hypertension	14.9	9.9	15.7	18.2	18.5	17.5	30.1
	Primary glomerulonephritis	19.1	22.5	20.0	9.1	10.2	10.5	7.0
	Other/Unknown	21.3	28.2	21.4	24.2	21.1	21.3	14.0
2g	Medical coverage (% of 2a; sums to 100%)							
Ū	Employer group only	29.8	18.3	27.1	24.2	12.7	12.3	12.3
	Medicare only	27.7	21.1	18.6	31.8	29.7	30.9	33.8
	Medicaid only	6.4	9.9	7.1	7.6	12.8	13.1	12.8
	Medicare and Medicaid only	17.0	18.3	22.9	15.2	12.1	11.0	12.8
	Medicare and other	6.4	12.7	10.0	10.6	19.7	20.0	16.8
	Other/Unknown	12.8	19.7	12.9	10.6	11.4	10.5	7.4
	None	0.0	0.0	1.4	0.0	1.6	2.2	4.1
2h	Median body mass index *5 (Median; Weight/Height^2)							
	Male	25.4	26.0	25.2	25.0	27.8	28.4	28.1
	Female	28.7	24.8	26.7	27.2	29.3	29.3	29.2
2i	Employment *6							
	Six months prior to ESRD treatment	53.8	38.7	44.4	61.9	35.2	37.4	34.4
	At first ESRD treatment	38.5	32.3	36.1	47.6	27.2	27.9	25.0
2j	Primary modality (% of 2a; sums to 100%)							
-5	Hemodialysis	42.6	57.7	48.6	60.6	88.9	85.8	89.4
	CAPD/CCPD	57.4	42.3	51.4	39.4	11.1	14.2	10.6
	Other/Unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2k	Number of incident hemodialysis patients (n)	20	41	34	40	17.4	14.8	14.9
21	Access used at first outpatient dialysis (% of 2k; sums to 100%)					2		
	Arteriovenous fistula	25.0	24.4	20.6	22.5	26.5	24.6	16.6
	Arteriovenous graft	15.0	9.8	2.9	2.5	3.4	3.5	3.1
	Catheter	60.0	65.9	76.5	75.0	70.0	71.8	80.1
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.1	0.1	0.2
2m	Arteriovenous fistula placed (% of 2k)	40.0	39.0	50.0	32.5	44.8	42.0	32.2

(continued)

TABLE 2 (cont.): Characteristics of New Dialysis Patients *1 , 2014-2017 (Form CMS-2728)

			This I	acility		Region	nal Averages	*2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
	Average Lab Values Prior to Dialysis *3							
2n	Hemoglobin (g/dL [3-18])	9.6	9.4	9.2	9.1	9.4	9.6	9.3
20	Serum albumin (g/dL [0.8-6.0])	3.9	4.2			3.2	3.3	3.2
2p	Serum creatinine (mg/dL [0-33])	7.0	7.2	6.9	7.2	6.7	6.3	6.4
2q	GFR (mL/min [0-30])	9.6	9.4	9.9	10.5	10.0	10.5	10.7
	Care Prior to ESRD Therapy							
2r	Received ESA prior to ESRD (% of 2a)	23.4	38.0	40.0	36.4	20.1	19.8	13.6
2s	Pre-ESRD nephrologist care (% of 2a; sums to 100%) *7							
	No	12.8	22.5	8.6	15.2	15.4	16.2	19.7
	Yes, < 6 months	6.4	18.3	22.9	7.6	16.5	15.2	14.5
	Yes, 6-12 months	17.0	16.9	22.9	16.7	16.9	19.5	20.0
	Yes, > 12 months	61.7	42.3	44.3	57.6	45.7	44.6	31.5
	Unknown/Missing	2.1	0.0	1.4	3.0	5.5	4.5	14.3
2t	Informed of transplant options (% of 2a)	63.8	64.8	60.0	51.5	78.8	81.1	88.3
2u	Patients not informed of transplant options (n)	17	25	28	32	4.1	3.3	1.9
2v	Reason not informed (% of 2u; may not sum to 100%) *8							
	Medically unfit	47.1	40.0	46.4	40.6	43.1	45.2	33.6
	Unsuitable due to age	0.0	0.0	0.0	15.6	7.8	12.4	25.2
	Psychologically unfit	0.0	12.0	3.6	6.3	1.8	1.7	2.8
	Patient declined information	0.0	0.0	0.0	0.0	1.5	1.6	2.1
	Patient has not been assessed	52.9	28.0	42.9	31.3	38.0	35.3	40.3
	Comorbid Conditions							
2w	Pre-existing comorbidity (% yes of 2a) *9							
	Congestive heart failure	31.9	18.3	24.3	34.8	30.6	28.8	28.8
	Atherosclerotic heart disease *9	25.5	15.5	17.1	15.2	17.1	17.6	13.4
	Other cardiac disorder *9	19.1	14.1	15.7	13.6	17.5	17.0	20.1
	CVD, CVA, TIA	17.0	9.9	10.0	10.6	8.1	8.5	8.6
	Peripheral vascular disease	8.5	7.0	14.3	15.2	11.0	11.5	9.6
	History of hypertension	89.4	84.5	84.3	86.4	86.8	85.5	88.2
	Diabetes*9	57.4	47.9	54.3	65.2	63.0	62.7	64.1
	Diabetes on insulin	34.0	36.6	41.4	34.8	43.7	43.5	43.1
	COPD	6.4	4.2	5.7	3.0	6.8	7.6	9.4
	Current smoker	10.6	4.2	2.9	6.1	6.1	6.9	6.5
	Cancer	6.4	8.5	5.7	4.5	7.8	7.7	7.0
	Alcohol dependence	0.0	1.4	0.0	0.0	1.2	1.6	1.6
	Drug dependence	6.4	8.5	4.3	9.1	3.2	2.3	1.3
	Inability to ambulate	10.6	7.0	7.1	13.6	3.6	4.1	7.3
	Inability to transfer	14.9	1.4	4.3	6.1	1.5	1.4	3.9
2x	Average number of comorbid conditions	3.4	2.7	2.9	3.2	3.1	3.1	3.1

^[*1] See Guide, Section V.

^[*2] Values are shown for the average facility.

^[*3] For continuous variables, summaries include only responses in range indicated in brackets.

^{[*4] &#}x27;Asian' includes Indian sub-continent. 'Native American' includes Alaskan Native. 'White' includes Middle Eastern and Arabian.

^[*5] The median BMI is computed for adult patients at least 20 years old with height, weight, and BMI values in acceptable ranges. Acceptable range for height, weight, and BMI are 122-208 cm, 32-318 kg, and 10-55, respectively.

^[*6] Full-time, part-time, or student (% of 18-60 year olds).

^[*7] Values may not sum to exactly 100% because of patients that received nephrology care but duration unknown (0.01% in US in 2017).

^[*8] Values may not sum to exactly 100% because of patients for which multiple reasons are selected, or no reason is selected.

^{[*9] &#}x27;Atherosclerotic heart disease' includes ischemic heart disease (coronary artery disease) and myocardial infarction. 'Other cardiac disorder' includes cardiac arrest, cardiac dysrhythmia, and pericarditis. 'Diabetes' includes patients with diabetes as the primary cause of ESRD.

TABLE 3: Mortality Summary for All Dialysis Patients (2014-17) & New Dialysis Patients (2014-16) *1

		'		This Fa	cility		Regional Averages *2			
	Measure Name	2014	2015	2016	2017	2014-2017	State	Network	U.S.	
	All Patients: Death Counts						•	2014-2017		
3a	Patients (n=number)	532	551	461	356	1900 *8	93.6	82.1	93.7	
3b	Patient-years (PY) at risk (n)	373.6	383.7	283.9	252.2	1293 *8	65.4	57.9	63.6	
3c	Deaths (n)	59	61	53	51	224*8	11.7	10.4	11.1	
3d	Expected deaths (n)	58.1	61.0	49.5	44.6	213*8	11.7	10.5	11.1	
3e	Withdrawal from dialysis prior to death (% of 3c)	45.8	44.3	43.4	49.0	45.5	38.8	41.0	25.1	
3f	Death due to Infections (% of 3c)	20.3	11.5	18.9	13.7	16.1	14.2	13.0	10.9	
	Death due to Cardiac causes (% of 3c)	30.5	37.7	58.5	35.3	40.2	39.5	39.5	44.6	
	Death due to Liver disease (% of 3c)	1.7	0.0	0.0	0.0	0.4	1.6	1.9	1.6	
3g	Dialysis unrelated deaths *3 (n; excluded from SMR)	0	1	0	0	1 *8	0.1	0.1	0.1	
	All Patients: Standardized Mortality Ratio (SMR)									
3h	SMR *4	1.01	1.00	1.07	1.14	1.05	1.00	0.98	1.00	
3i	P-value *5	0.943	0.999	0.659	0.371	0.476	n/a	n/a	n/a	
3j	Confidence interval for SMR *6									
	High (97.5% limit)	1.31	1.29	1.40	1.50	1.20	n/a	n/a	n/a	
	Low (2.5% limit)	0.77	0.77	0.80	0.85	0.92	n/a	n/a	n/a	
3k	SMR percentiles for this facility *7									
	In this State	48	57	66	66	66	n/a	n/a	n/a	
	In this Network	54	60	64	68	65	n/a	n/a	n/a	
	In the U.S.	56	53	61	68	61	n/a	n/a	n/a	
	New Patients: First Year Death Counts	2014	2015	2016		2014-2016		2014-2016		
31	New patients (n=number)	47	71	70		188*8	18.0	16.0	16.7	
3m	Patient-years (PY) at risk (n)	41.5	60.2	63.3		165 *8	16.1	14.2	14.7	
3n	Deaths (n)	7	13	11		31 *8	3.0	2.8	3.2	
3о	Expected deaths (n)	8.2	12.0	9.6		29.8*8	3.4	3.1	3.2	
3p	Withdrawal from dialysis prior to death (% of 3n)	71.4	38.5	36.4		45.2	41.8	43.7	27.1	
3q	Death due to Infections (% of 3n)	0.0	15.4	27.3		16.1	12.9	11.3	9.9	
	Death due to Cardiac causes (% of 3n)	57.1	23.1	27.3		32.3	33.2	33.6	39.7	
	Death due to Liver disease (% of 3n)	0.0	0.0	0.0		0.0	3.0	3.6	2.7	
	New Patients: First Year Standardized Mortality									
	Ratio (SMR)									
3r	SMR *4	0.85	1.08	1.15		1.04	0.88	0.92	1.00	
3s	P-value *5	0.851	0.852	0.725		0.871	n/a	n/a	n/a	
3t	Confidence interval for SMR *6									
	High (97.5% limit)	1.76	1.85	2.06		1.48	n/a	n/a	n/a	
	Low (2.5% limit)	0.34	0.58	0.57		0.71	n/a	n/a	n/a	
3u	First Year SMR percentiles for this facility *7									
	In this State	47	71	73		71	n/a	n/a	n/a	
	In this Network	47	70	65		63	n/a	n/a	n/a	
	In the U.S.	46	60	63		58	n/a	n/a	n/a	

^[*1] See Guide, Section VI.

^[*2] Values are shown for the average facility, annualized.

^[*3] Defined as deaths due to street drugs and accidents unrelated to treatment.

^[*4] Calculated as a ratio of deaths to expected deaths (3c to 3d for all patients, 3n to 3o for new patients); not shown if there are fewer than 3 expected deaths.

^[*5] A p-value less than 0.05 indicates that the difference between the actual and expected mortality is probably real and is not due to random chance alone, while a p-value greater than or equal to 0.05 indicates that the difference could plausibly be due to random chance.

^[*6] The confidence interval range represents uncertainty in the value of the SMR due to random variation.

^[*7] All facilities are included in ranking, regardless of the number of expected deaths.

^[*8] Sum of 4 years (all patients) or 3 years (new patients) used for calculations; should not be compared to regional averages.

TABLE 4: Hospitalization Summary for Medicare Dialysis Patients *1 , 2014-2017

				This Fa	cility			ional Averag Year, 2014-2	
	Measure Name	2014	2015	2016	2017	2014-2017	State	Network	U.S.
	Medicare Dialysis Patients					-			
4a	Medicare dialysis patients (n)	388	398	327	261	1374 *3	71.6	63.0	71.2
4b	Patient-years (PY) at risk (n)	249.7	250.3	183.8	167.0	850.8*3	46.6	40.6	43.6
	Days Hospitalized Statistics								
4c	Total days hospitalized (n)	3,172	2,483	2,718	2,215	10,588*3	486.0	404.8	588.0
4d	Expected total days hospitalized (n)	3,436.7	3,302.8	2,591.1	2,670.4	12001.1 *3	620.4	533.6	589.
4e	Standardized Hospitalization Ratio (Days)*4	0.92	0.75	1.05	0.83	0.88	0.78	0.76	1.00
4f	P-value *5	0.676	0.146	0.661	0.345	0.443	n/a	n/a	n/a
4g	Confidence interval for SHR (Days) *6								
	High (97.5% limit)	1.29	1.10	1.47	1.19	1.19	n/a	n/a	n/a
	Low (2.5% limit)	0.68	0.53	0.78	0.60	0.68	n/a	n/a	n/a
4h	Percentiles for this facility (Days) *7								
	In this State	80	56	89	58	75	n/a	n/a	n/a
	In this Network	77	56	90	65	79	n/a	n/a	n/a
	In the U.S.	50	29	64	37	42	n/a	n/a	n/a
	Admission Statistics								
4i	Total admissions (n)	355	392	321	333	1,401 *3	75.7	63.5	79.5
4j	Expected total admissions (n)	457.6	446.0	342.1	351.7	1,597.4 *3	84.5	72.9	79.5
4k	Standardized Hospitalization Ratio (Admissions) *4	0.78	0.88	0.94	0.95	0.88	0.90	0.87	1.00
41	P-value *5	0.067	0.333	0.714	0.772	0.271	n/a	n/a	n/a
4m	Confidence interval for SHR (Admissions) *6								
	High (97.5% limit)	1.02	1.13	1.24	1.25	1.10	n/a	n/a	n/a
	Low (2.5% limit)	0.61	0.70	0.73	0.74	0.72	n/a	n/a	n/a
4n	Percentiles for this facility (admissions) *7								
	In this State	34	50	69	56	48	n/a	n/a	n/a
	In this Network	40	54	70	61	54	n/a	n/a	n/a
	In the U.S.	22	36	45	46	32	n/a	n/a	n/a
4o	Diagnoses associated with hospitalization (% of 4a) *8								
	Septicemia	10.8	13.6	11.9	15.3	12.7	11.8	11.0	11.2
	Acute myocardial infarction	4.1	2.8	5.8	9.6	5.2	4.9	4.7	4.4
	Congestive heart failure	17.5	19.6	22.3	28.0	21.3	24.0	22.3	23.8
	Cardiac dysrhythmia	13.7	15.1	16.2	16.5	15.2	14.8	13.7	14.1
	Cardiac arrest	1.0	1.8	3.1	1.9	1.9	2.0	1.8	2.1
4p	One day admissions (% of 4i)	12.4	16.6	10.6	11.1	12.8	12.5	11.6	10.1
4q	Average length of stay (days per admission; 4c/4i)	8.9	6.3	8.5	6.7	7.6	6.4	6.4	7.4

(continued)

NKC - SEATTLE KIDNEY CENTER State: WA Network: 16 CCN: 502500

TABLE 4 (cont.): Hospitalization Summary for Medicare Dialysis Patients *1, 2014-2017

				This Fa	cility		Regional Averages *2, per Year, 2014-2017			
	Measure Name	2014	2015	2016	2017	2014-2017	State	Network	U.S.	
	Emergency Department (ED) Statistics									
4r	Total ED visits (n)	670	662	569	556	2,457 *3	144.2	122.1	138.4	
4s	Expected total ED visits (n)	796.7	814.8	622.8	577.4	2,811.7*3	148.1	129.0	138.6	
4t	Standardized Hospitalization Ratio (ED) *4	0.84	0.81	0.91	0.96	0.87	0.97	0.95	1.00	
4u	P-value *5	0.250	0.167	0.636	0.918	0.331	n/a	n/a	n/a	
4v	Confidence interval for SHR (ED) *6									
	High (97.5% limit)	1.11	1.08	1.24	1.31	1.13	n/a	n/a	n/a	
	Low (2.5% limit)	0.66	0.64	0.71	0.74	0.70	n/a	n/a	n/a	
4w	Percentiles for this facility (ED) *7									
	In this State	25	19	42	44	28	n/a	n/a	n/a	
	In this Network	34	26	48	54	36	n/a	n/a	n/a	
	In the U.S.	30	25	41	48	31	n/a	n/a	n/a	
4x	Patients with ED visit (% of 4a)	58.0	57.3	59.3	63.2	59.1	63.8	63.2	61.9	
4y	ED visits that result in hospitalization (% of 4r)	37.6	45.5	43.6	47.5	43.3	41.1	39.3	47.0	
4z	Admissions that originate in the ED (% of 4i)	71.0	76.8	77.3	79.3	76.0	78.2	75.5	81.8	
	Readmission Statistics							2017		
4aa	Index discharges (n)	339	378	300	327		78.3	63.5	76.4	
4ab	Total readmissions (n)	81	91	69	92		20.5	15.4	21.0	
4ac	Expected total readmissions (n)	97	105	83	95		22.4	18.2	21.4	
4ad	Standardized Readmission Ratio (SRR)	0.83	0.87	0.83	0.97		0.97	0.91	1.04	
4ae	P-value *5	0.118	0.194	0.160	0.565		n/a	n/a	n/a	
4af	Confidence interval for SRR *6									
	High (97.5% limit)	1.09	1.11	1.07	1.18		n/a	n/a	n/a	
	Low (2.5% limit)	0.61	0.65	0.61	0.79		n/a	n/a	n/a	

^[*1] Based on patients with Medicare as primary insurer; see *Guide, Section VII*.

^[*2] Values are shown for the average facility, annualized.

^[*3] Sum of 4 years used for calculations; should not be compared to regional averages.

^[*4] Standardized Ratios are calculated as a ratio of actual to expected events (4c/4d for days, 4i/4j for admissions, 4r/4s for ED visits, and 4ab/4ac for readmissions). SHRs are not shown if there are less than 5 patient years at risk. SRR is not shown if fewer than 11 index discharges in the year.

^[*5] A p-value less than 0.05 indicates that the difference between the actual and expected event is probably real and is not due to random chance alone, while a p-value greater than or equal to 0.05 indicates that the difference could plausibly be due to random chance.

greater than or equal to 0.05 indicates that the difference could plausibly be due to random chance.

[*6] The confidence interval range represents uncertainty in the value of the standardized hospitalization and readmission ratios (SHRs and SRR) due to random variation.

^[*7] All facilities are included in ranking, regardless of the number of patient years at risk.

^[*8] Includes diagnoses present at admission and diagnoses added during the hospital stay.

NKC - SEATTLE KIDNEY CENTER State: WA Network: 16 CCN: 502500

TABLE 5: Transplantation Summary for Dialysis Patients under Age 70 *1, 2014-2017

				This Fa	cility	'		ional Averag Year, 2014-2	
	Measure Name	2014	2015	2016	2017	2014-2017	State	Network	U.S.
	All patients								
5a	Eligible patients (n)	393	414	336	245	1388 *10	64.8	56.7	64.0
5b	Transplants (n)	36	20	13	14	83 *10	2.5	2.2	2.0
5c	Donor type (sums to 5b) *3								
	Living donor (n)	9	3	5	3	20 *10	0.5	0.5	0.5
	Deceased donor (n)	27	17	8	11	63 *10	2.1	1.7	1.5
	Patients who have not Previously Received								
	a Transplant								
5d	Eligible patients (n)	327	342	279	209	1157 *10	58.7	51.5	58.7
5e	Patient years (PY) at risk (n)	221.3	230.0	164.3	146.0	761.6*10	40.9	36.3	40.3
5f	First transplants *4 (n)	32	19	9	13	73 *10	2.2	1.9	1.7
5g	Expected first transplants (n)	9.7	10.0	7.0	6.5	33.2*10	1.8	1.6	1.7
	Standardized 1st Transplantation Ratio (STR) *5								
5h	STR *6					2.20	1.27	1.24	1.00
5i	P-value *7					< 0.01	n/a	n/a	n/a
5j	Confidence interval for STR *8								
	High (97.5% limit)					2.76	n/a	n/a	n/a
	Low (2.5% limit)					1.72	n/a	n/a	n/a
5k	STR percentiles for this facility *9								
	In this State					86	n/a	n/a	n/a
	In this Network					87	n/a	n/a	n/a
	In the U.S.					90	n/a	n/a	n/a

^[*1] See Guide, Section VIII.

^[*2] Values are shown for the average facility, annualized.

^[*3] Values may not sum to 5b due to unknown donor type.

^[*4] Among first transplants that occurred after the start of dialysis from 2014-2017, 3.5% of transplants in the U.S. were not included because the transplant occurred fewer than 90 days after the start of ESRD and 1.1% were not included because the patient was not assigned to a facility at time of transplant.

^[*5] This section is calculated for the 4-year period only and not reported if there are fewer than 3 expected transplants.

^[*6] Standardized 1st Transplantation Ratio is calculated as a ratio of actual (5f) to expected (5g) transplants.

^[*7] A p-value less than 0.05 indicates that the difference between the actual and expected transplants is probably real and is not due to random chance, while a p-value greater than or equal to 0.05 indicates that the difference is plausibly due to random chance.

^[*8] The confidence interval range represents uncertainty in the value of the STR due to random variation.

^[*9] All facilities are included in ranking, regardless of the number of expected transplants. [*10] Sum of 4 years used for calculations; should not be compared to regional averages.

TABLE 6: Waitlist Summary for Dialysis Patients under Age 70 Treated on December 31st of Each Year *1, 2014-2017

			This I	acility		Region	nal Averages	*2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
6a	Eligible patients on 12/31 (n)	286	235	187	165	50.7	44.8	46.2
6b	Patients on the waitlist (% of 6a)	35.7	31.9	28.9	27.3	17.3	15.1	20.1
6c	P-value *3 (compared to U.S. value)	< 0.01	< 0.01	< 0.01	0.016	n/a	n/a	n/a
6d	Patients on the waitlist by subgroup (%) *4							
	Age < 40	44.4	25.0	52.4	42.1	27.4	23.0	29.5
	Age 40-69	34.0	32.7	25.9	25.3	15.7	13.9	19.0
	Male	36.9	32.3	29.5	29.5	18.1	15.5	21.3
	Female	34.5	31.5	28.3	24.7	16.0	14.5	18.6
	African American	25.3	18.5	24.2	22.0	17.0	16.0	18.7
	Asian/Pacific Islander	49.2	48.3	38.6	43.9	22.0	21.6	30.8
	Native American	0.0	0.0	0.0	0.0	11.5	10.9	13.4
	White, Hispanic	52.0	40.0	40.0	11.1	14.1	13.5	22.6
	White, non-Hispanic	32.7	30.5	25.4	21.6	16.9	14.3	19.0
	Other/unknown race			0.0	66.7	25.0	21.0	22.1
	Diabetes	28.7	27.6	26.7	24.2	13.0	10.8	16.1
	Non-diabetes	40.4	35.0	30.4	29.3	21.1	19.0	23.6
	Previous kidney transplant	35.7	32.6	13.8	9.1	30.8	27.1	34.4
	No previous kidney transplant	35.7	31.8	31.6	30.1	16.0	14.0	18.9
	< 2 years since start of ESRD	27.1	29.2	33.3	41.7	16.0	13.5	14.2
	2-4 years since start of ESRD	41.7	33.7	31.0	22.6	21.1	19.1	24.9
	5+ years since start of ESRD	40.0	33.3	18.8	14.0	15.2	13.4	21.9

n/a = not applicable.

[*4] A missing value indicates that there were no eligible patients in the subgroup.

^[*1] See Guide, Section IX.

^[*2] Values are shown for the average facility.

^[*3] Facility waitlist percentage is compared to the U.S. waitlist percentage for that year: 24.0% (2014), 22.6% (2015), 21.3% (2016), 20.1% (2017). A p-value greater than 0.05 indicates that the difference between percent of patients wailisted at the facility and national percentage is plausibly due to random chance.

NKC - SEATTLE KIDNEY CENTER State: WA Network: 16 CCN: 502500

TABLE 7: Influenza Vaccination Summary for Medicare Dialysis Patients Treated on December 31st of Each Year*1, Flu Seasons August 2014-December 2017

			This I	acility		Regional Average		es *2
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
							2017	
7a	Eligible patients on 12/31 (n)	254	207	174	160	49.8	43.4	45.0
7b	Patients vaccinated between Aug. 1 and Dec. 31 (% of 7a)	77.2	73.9	74.1	70.6	76.7	76.3	72.1
7c	P-value *3 (for 7b compared to U.S. value *4)	0.133	0.450	0.077	0.367	n/a	n/a	n/a
							2016	
7d	Patients vaccinated between Aug 1 and Mar 31 of following year (% of 7a)	78.0	73.9	74.7		74.0	72.5	69.6
7e	P-value *3 (for 7d compared to U.S. value *5)	0.107	0.521	0.079		n/a	n/a	n/a
							2017	
7f	Patients vaccinated between Aug 1 and Dec 31 by subgroup (%) *6							
	Age < 18					52.9	54.2	55.8
	Age 18-39	83.3	66.7	75.0	66.7	71.4	74.6	68.6
	Age 40-64	74.0	70.0	73.7	72.7	75.3	76.3	72.6
	Age 65-74	80.6	75.5	68.2	63.6	75.9	74.8	71.8
	Age 75+	76.2	81.6	80.4	75.0	81.9	78.8	72.7
	Male	77.6	69.2	77.1	73.0	75.7	75.7	72.0
	Female	76.7	80.0	70.5	67.6	77.9	77.0	72.2
	African American	76.0	75.9	78.0	61.8	71.5	70.0	69.9
	Asian/Pacific Islander	77.3	75.0	72.2	79.6	79.0	79.3	75.4
	Native American	100	100	100	100	78.5	76.8	79.6
	White	77.7	71.7	71.9	70.9	76.9	76.4	73.0
	Other/unknown race			50.0		85.2	81.8	68.6
	Hispanic	85.7	66.7	90.9	63.6	81.3	82.5	72.6
	< 1 year since start of ESRD	70.6	60.0	42.3	50.0	65.4	64.7	58.8
	1-2 years since start of ESRD	85.2	80.3	79.6	83.3	77.2	75.5	70.6
	3+ years since start of ESRD	74.1	73.9	79.8	70.7	79.7	79.9	76.2

^[*1] Based on patients with Medicare as primary insurer; see *Guide*, *Section X*.

^[*2] Values are shown for the average facility.
[*3] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the facility and national percentage is plausibly due to random chance.

^[*4] Compared to the U.S. value for that year and time period (8/1-12/31): 73.9% (2014), 73.2% (2015), 68.9% (2016), 72.1% (2017).

^[*5] Compared to the U.S. value for that year and time period (8/1-3/31): 74.4% (2014), 73.8% (2015), 69.6% (2016). [*6] A missing value indicates that there were no eligible patients in the subgroup.

TABLE 8: Anemia Management Summaries for Adult Dialysis Patients *1, 2014-2017

			This I	acility		Region	nal Averages	*2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
	Hemoglobin and ESA-CROWNWeb							
8a	Eligible adult patients (n) *3	486	484	369	303	95.5	83.7	85.3
8b	Eligible adult patient-months (n) *4	4,111	4,028	2,815	2,604	793.6	713.0	748.7
8c	Average hemoglobin *5 (g/dL) (average of 8b)	10.8	10.9	10.8	10.8	10.9	10.9	10.8
8d	Hemoglobin categories (% of 8b; sums to 100%)							
	<10 g/dL	21.5	19.1	20.6	20.3	18.8	17.9	20.7
	10-<11 g/dL	33.9	34.1	30.7	31.8	33.6	33.1	33.8
	11-12 g/dL	28.9	30.0	33.8	32.2	30.8	31.2	29.8
	>12 g/dL	12.7	14.3	12.2	13.4	13.0	15.1	13.3
	Missing/Out of range	2.9	2.6	2.7	2.2	3.8	2.7	2.4
8e	ESA prescribed (% of 8b)	85.6	85.3	86.0	70.5	71.1	69.1	72.5
	Standardized Transfusion Ratio (STrR)							
8f	Eligible adult Medicare patients (n)	334	335	269	192	64.6	58.0	58.7
8g	Patient years (PY) at risk (n)	193	203	138	108	37.8	34.1	34.9
8h	Total transfusions (n)	65	50	57	32	10.8	9.8	13.1
8i	Expected total transfusions (n)	87.0	86.2	58.8	43.7	14.1	12.7	13.2
8j	Standardized Transfusion Ratio *6	0.75	0.58	0.97	0.73	0.76	0.77	1.01
	Upper Confidence Limit (97.5%)	1.17	0.96	1.55	1.38	n/a	n/a	n/a
	Lower Confidence Limit (2.5%)	0.50	0.38	0.64	0.42	n/a	n/a	n/a
8k	P-value *7	0.218	0.034	0.990	0.360	n/a	n/a	n/a
	Hemoglobin-Medicare Claims *8							
81	Eligible adult hemodialysis (HD) patients (n)	151	147	126	106	39.3	32.6	36.2
8m	Hemoglobin categories among HD pts (% of 81; sums to 100%)							
	< 10 g/dL	23.8	18.4	16.7	15.1	12.6	12.0	16.8
	10-<11 g/dL	68.2	72.8	51.6	60.4	65.3	65.6	63.9
	11-12 g/dL	7.9	8.8	31.7	24.5	21.7	22.0	19.0
	> 12 g/dL	0.0	0.0	0.0	0.0	0.3	0.3	0.3
8n	Eligible adult peritoneal dialysis (PD) patients (n)	88	90	45	36	4.1	3.8	3.0
80	Hemoglobin categories among PD pts (% of 8n; sums to 100%)							
	< 10 g/dL	10.2	11.1	13.3	13.9	21.4	22.3	26.2
	10-<11 g/dL	76.1	73.3	68.9	63.9	62.0	61.2	56.7
	11-12 g/dL	13.6	15.6	17.8	22.2	15.6	15.7	16.5
	> 12 g/dL	0.0	0.0	0.0	0.0	1.0	0.8	0.6

^[*1] See Guide, Section XI. Transfusion and claims-based summaries include adult Medicare Dialysis Patients only.

^[*2] Values are shown for the average facility.

^[*3] Includes those who switch between HD and PD during the month and patients for whom modality is unknown.

^[*4] Patients may be counted up to 12 times per year.

^[*5] Based on in-range values; see Guide for range values.

^[*6] Calculated as a ratio of observed transfusions to expected transfusions (8h to 8i); not shown if there are fewer that 10 patient-years at risk for transfusions.

[*7] A p-value less than 0.05 indicates that the difference between the actual and expected transfusion is probably real and is not due to random chance alone, while a p-value greater than or equal to 0.05 indicates that the difference could plausibly be due to random chance.

^[*8] Among ESA-treated dialysis patient with ESRD for more than 90 days and 4 or more claims at this facility.

TABLE 9: Dialysis Adequacy Summaries for All Dialysis Patients *1 , 2014-2017

			This I	acility		Region	nal Averages	*2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
	Hemodialysis (HD) Adequacy					,		
9a	Eligible adult HD patients (n)	256	257	222	200	84.9	73.3	78.5
9b	Eligible adult HD patient-months (n) *3	2,128	2,121	1,774	1,725	701.2	619.3	687.6
9c	Average serum albumin (g/dL) (average of 9b)	4.0	3.9	3.9	3.8	3.8	3.8	3.8
9d	Serum albumin categories (% of 9b; sums to 100%)							
	< 3.0 g/dL	2.9	2.8	3.2	4.8	3.2	3.1	3.6
	3.0-<3.5 g/dL	8.4	7.8	10.9	15.2	13.8	13.8	14.3
	3.5-<4.0 g/dL	30.8	36.4	38.1	41.7	46.4	47.2	48.0
	>=4.0 g/dL	54.2	49.3	45.6	36.9	32.4	32.8	31.1
	Missing	3.8	3.6	2.2	1.4	4.2	3.1	2.9
9e	Ultrafiltration rate average *4 (ml/kg/hr) (average of 9b)	4.7	5.0	4.8	5.0	6.8	7.1	7.8
9f	Ultrafiltration rate categories (% of 9b; sums to 100%)							
	<=13 ml/kg/hr	88.5	87.8	91.2	90.0	86.1	85.9	83.0
	>13 ml/kg/hr	1.5	2.7	1.7	2.1	5.5	6.6	9.4
	Missing/Out of range	10.1	9.5	7.1	7.9	8.3	7.6	7.6
9g	Eligible adult HD Kt/V patients (n) *5	181	191	180	164	79.4	68.0	75.6
9h	Eligible adult HD Kt/V patient-months (n) *3 *5	1,469	1,529	1,445	1,429	647.0	565.0	654.9
9i	Average Kt/V *4 (average of 9h)	1.7	1.7	1.7	1.7	1.7	1.7	1.6
9j	Kt/V categories (% of 9h; sums to 100%)							
	<1.2	4.4	4.5	5.3	4.2	2.5	2.2	2.1
	1.2-<1.8	63.9	63.3	63.0	58.0	66.1	67.5	72.0
	>=1.8	29.4	30.0	30.5	37.1	29.3	28.7	24.2
	Missing/Out of range	2.3	2.2	1.2	0.7	2.0	1.6	1.7
	Peritoneal Dialysis (PD) Adequacy							
9k	Eligible adult PD patients (n)	236	229	156	108	18.0	21.2	20.7
91	Eligible adult PD patient-months (n) *3	1,977	1,905	1,033	872	136.8	164.2	164.8
9m	Average weekly Kt/V *4 *6 (average of 9l)	2.3	2.3	2.4	2.3	2.2	2.3	2.2
9n	Weekly Kt/V categories (% of 9l; sums to 100%) *5							
	<1.7	3.6	5.8	4.0	5.5	5.5	5.0	5.2
	1.7-<2.5	67.8	67.0	65.0	67.8	68.3	66.8	66.2
	>=2.5	26.8	25.4	27.8	22.2	22.5	25.7	24.4
	Missing/Out of range	1.7	1.8	3.3	4.5	3.7	2.5	4.2
9o	Average serum albumin (g/dL) (average of 91)	3.8	3.7	3.7	3.6	3.5	3.5	3.5
9p	Serum albumin categories (% of 91; sums to 100%)							
-	< 3.0 g/dL	2.9	3.7	6.2	7.8	10.5	10.8	11.4
	3.0-<3.5 g/dL	15.3	18.5	18.3	27.8	32.3	30.5	31.3
	3.5-<4.0 g/dL	46.1	46.4	47.5	44.7	41.1	42.3	40.7
	>=4.0 g/dL	33.4	28.6	24.1	15.3	11.9	13.3	13.1
	Missing	2.2	2.8	3.9	4.5	4.2	3.1	3.5

^[*1] See Guide, Section XII. Unless otherwise noted, all summaries are based on data reported in CROWNWeb and the patient must be on HD (or PD) for the entire reporting month to be included in patient counts and summaries.

[*2] Values are shown for the average facility.

[*3] Patients may be counted up to 12 times per year.

^[*4] Based on in-range values; see Guide for range values.

^[*5] Kt/V summaries are supplemented with Medicare claims if missing in CROWNWeb. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "Determination of Thrice Weekly Dialysis" for more information. The most recent value over a 4-month period is selected for PD Kt/V.

TABLE 10: Mineral Metabolism Summaries for All Adult Dialysis Patients *1 , 2014-2017

			This F	acility		Region	nal Averages	*2, 2017
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
10a	Eligible adult patients (n) *3	486	484	369	303	95.5	83.7	85.3
10b	Eligible adult patient-months (n) *3 *4	4,111	4,028	2,815	2,604	793.6	713.0	748.7
10c	Average phosphorous *5 (mg/dL) (average of 10b *6)	5.3	5.4	5.5	5.3	5.5	5.4	5.3
10d	Phosphorous categories (% of 10b *6; sums to 100%)							
	<3.5 mg/dL	8.8	6.8	9.2	10.0	7.6	7.7	8.6
	3.5-4.5 mg/dL	25.2	25.2	22.0	26.2	22.7	23.7	25.0
	4.6-5.5 mg/dL	25.6	25.3	23.5	23.9	27.5	28.7	30.0
	5.6-7.0 mg/dL	24.6	25.0	25.6	23.5	22.4	22.3	20.8
	>7.0 mg/dL	12.7	14.1	16.2	13.9	15.6	14.3	12.6
	Missing/Out of range	3.2	3.5	3.6	2.6	4.2	3.2	3.0
10e	Average calcium uncorrected *5 (mg/dL) (average of 10b)	9.1	9.1	9.2	9.0	9.0	9.0	8.9
10f	Calcium uncorrected categories (% of 10b; sums to 100%)							
	<8.4 mg/dL	15.1	12.7	11.4	15.8	15.9	15.4	16.9
	8.4-10.2 mg/dL	76.4	81.6	84.2	81.0	79.0	80.3	79.0
	>10.2 mg/dL	5.6	2.6	1.7	1.2	1.1	1.2	1.3
	Missing/Out of range	3.0	3.1	2.7	2.0	4.0	3.0	2.8
10g	Average uncorrected serum or plasma calcium > 10.2 mg/dL *5 *7	5.7	2.8	2.0	1.6	2.6	2.1	2.1

^[*1] See Guide, Section XIII. Summaries are based on data reported in CROWNWeb and the patient must be assigned to the facility the entire month to be included.

^[*2] Values are shown for the average facility.

^[*3] Includes patients on ESRD more than 90 days who switch between HD and PD during the month and patients for whom modality is unknown.
[*4] Patients may be counted up to 12 times per year.

^[*5] Based on in-range values; see Guide for range values.

^[*6] Eligible patients included in the phosphours summaries differ slightly from what is reported in 10b since it includes patient-months within the first 90 days of ESRD. [*7] Hypercalcemia is avearaged from uncorrected serum or plasma calcium values over a rolling 3-month period.

NKC - SEATTLE KIDNEY CENTER State: WA Network: 16 CCN: 502500

TABLE 11: Vascular Access Information for All Dialysis Patients and Access-Releated Infection Summaries for All Medicare Patients *1 , 2014-2017

			This Facility			Regional Averages *2, 2017		
	Measure Name	2014	2015	2016	2017	State	Network	U.S.
	Vascular Access							
11a	Prevalent adult hemodialysis patients (n)	265	275	240	217	91.2	78.7	83.9
11b	Prevalent adult hemodialysis patient-months *3 (n)	2,189	2,210	1,842	1,811	745.4	656.5	725.2
11c	Vascular access type in use (% of 11b; sums to 100%)							
	Arteriovenous fistula	69.5	67.6	67.7	64.2	68.1	67.3	62.6
	Arteriovenous graft	17.8	20.0	18.0	15.7	11.9	14.0	17.7
	Catheter	10.3	10.7	12.9	18.7	16.1	15.9	17.3
	Other/Missing	2.3	1.8	1.4	1.4	3.9	2.8	2.4
11d	Arteriovenous fistulae in place (% of 11b) *4	70.6	67.8	68.1	64.5	69.1	68.5	63.8
11e	Catheter only \geq 90 days (% of 11b) *5	5.2	4.1	6.8	11.5	9.6	9.4	10.7
	Vascular Access at First Treatment							
11f	Incident hemodialysis patients (n)	17	41	36	40	17.4	15.3	15.7
11g	Vascular access type in use (% of 11f; sums to 100%)							
	Arteriovenous fistula	17.6	19.5	19.4	20.0	25.1	22.5	15.6
	Arteriovenous graft	17.6	9.8	5.6	5.0	3.4	3.9	3.5
	Catheter	64.7	68.3	75.0	67.5	68.3	69.9	76.3
	Other/Missing	0.0	2.4	0.0	7.5	3.2	3.7	4.6
11h	Arteriovenous fistulae in place (% of 11f)*4	17.6	19.5	19.4	20.0	25.9	23.6	17.1
	Infection: Peritoneal dialysis (PD)							
11i	Eligible PD patients (n)	186	185	122	89	9.5	10.0	7.3
11j	Eligible PD patient-months *3	1373	1402	737	653	65.9	69.7	51.7
11k	PD catheter infection rate per 100 PD patient-months *6	3.71	4.07	4.88	9.34	3.98	2.70	2.87
111	P-value *7 of 11k (compared to U.S. value) *8	0.036	0.010	< 0.01	< 0.01	n/a	n/a	n/a

^[*1] See Guide, Section XIV. Vascular Access type is based on data reported in CROWNWeb. For the prevalent summaries (rows 11a-11e), the patient must be assigned to the facility for the entire calendar month to be included. The PD infection summaries are based on Medicare Dialysis claims.

^[*2] Values are shown for the average facility.

^[*3] Patients may be counted up to 12 times per year per facility.

^[*4] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

^[*5] Catheter was used for treatment and has been in place for 90 days or more prior to treatment. Patient does not have an fistula or graft in place. Catheter is only access. Port access devices are reported as catheters for this project.

^[*6] The ICD-9 PD catheter infection code for PD patients is 996.68 which is effective thru 9/30/2015 and the ICD-10 PD catheter infection code for PD patients is T8571XA which is effective beginning 10/1/2015.

^[*7] A p-value greater than or equal to 0.05 indicates the differences between the percent of patients with infection at the facility and national percentage is plausibly due to random chance.

^[*8] Compared to U.S. value for that year: 2.85 (2014), 2.94 (2015), 2.88 (2016), and 2.87 (2017).

TABLE 12: Comorbidities Reported on Medicare Claims for Medicare Dialysis Patients Treated as of December 31st of Each Year *1 , 2014-2017

	Measure Name	•	This Facility				Regional Averages *2, 2017		
		2014	2015	2016	2017	State	Network	U.S.	
12a	Medicare dialysis patients on 12/31 (n)	260	247	183	169	52.5	46.5	48.6	
12b	Comorbidity (% yes of 12a)								
	Infections								
	AIDS/HIV positive	1.9	2.0	1.6	2.4	0.6	0.6	1.7	
	Dialysis access-related	7.3	11.7	15.3	17.8	8.7	8.3	9.2	
	Hepatitis B	1.9	2.0	3.3	4.1	1.6	1.2	1.6	
	Hepatitis other	7.7	9.3	10.4	11.2	6.6	5.6	5.7	
	Metastatic	3.8	3.6	3.8	3.0	3.0	2.9	3.0	
	Pneumonia	5.0	5.7	8.7	11.2	9.1	8.2	8.4	
	Tuberculosis	0.8	2.8	1.1	0.6	0.5	0.4	0.5	
	Other	34.6	33.2	42.1	43.2	35.8	35.4	35.6	
	Cardiovascular								
	Cardiac arrest	1.5	2.0	3.3	1.2	1.7	1.5	1.9	
	Cardiac dysrhythmia	30.8	30.8	37.7	36.7	38.4	37.1	36.9	
	Cerebrovascular disease	17.7	19.4	25.7	27.2	20.7	18.8	24.4	
	Congestive heart failure	33.5	39.7	46.4	52.7	51.8	49.9	52.9	
	Ischemic heart disease	29.6	38.9	48.1	47.9	46.3	44.3	49.4	
	Myocardial infarction	4.6	6.5	11.5	15.4	11.3	10.3	10.2	
	Peripheral vascular disease *3	35.8	39.7	45.4	39.6	40.1	37.7	44.2	
	Other								
	Alcohol dependence	1.2	2.0	2.2	2.4	3.3	3.0	2.9	
	Anemia	3.1	3.2	2.7	5.3	6.8	7.1	9.4	
	Cancer	11.9	13.4	16.9	14.8	11.0	10.6	11.1	
	Chronic obstructive pulmonary disease	20.0	23.5	22.4	24.9	30.3	30.3	32.2	
	Diabetes	55.0	53.0	59.0	62.7	63.8	62.6	67.9	
	Drug dependence	6.2	8.5	9.8	8.9	7.0	6.7	3.6	
	Gastrointestinal tract bleeding	3.5	2.8	8.7	3.0	4.3	4.3	4.5	
	Hyperparathyroidism	95.8	92.7	92.9	95.3	90.7	87.8	85.6	
12c	Average number of comorbid conditions	4.1	4.5	5.2	5.3	4.9	4.7	5.0	

n/a = not applicable [*1] Based on patients with Medicare as primary insurer on 12/31 each year. See *Guide, Section XV*.

^[*2] Values are shown for the average facility.

^[*3] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases.

TABLE 13: Facility Information *1, 2017

		This Facility	Regional Averages *2, 2017			
	Measure Name	2017	State	Network	U.S.	
13a	Organization	NORTHWEST KIDNEY CENTERS				
13b	Ownership	Non-profit				
13c	Initial Medicare certification date	09/16/1980				
13d	Number of stations	38				
13e	Services provided	Hemodialysis and Peritoneal Dialysis				
13f	Shifts after 5:00 pm	Yes				
13g	Dialyzer Reuse					
13h	CMS Certification Numbers (CCN) included in this report	502500				
13i	National Provider Identifier (NPI) *3	1346242542				
	Patient Placement					
13j	Patients treated during year from AFS Form-2744 (n)	386	117.2	100.8	103.3	
13k	Transferred into facility (% of 13j)	17.4	18.6	16.3	15.3	
131	Transferred out of facility (% of 13j)	21.5	18.1	16.3	15.5	
13m	Patients treated on 12/31 (n)	234	78.1	68.1	70.9	
13n	Medicare eligibility status (% of 13m; sums to 100% *4)					
	Medicare	77.8	81.8	84.7	64.9	
	Medicare application pending	1.3	0.6	0.6	0.6	
	Non-Medicare	20.9	17.6	14.7	34.5	
	Survey and Certfication *5					
13o	Date of last survey	01/24/2017	n/a	n/a	n/a	
13p	Type of survey	Recertification	n/a	n/a	n/a	
13q	Compliance condition after survey	Unknown				
13r	Number of CFC deficiencies cited	3	0.9	0.6	0.3	
13s	Number of Standard deficiencies cited	16	9.8	6.5	5.4	

^[*1] See Guide, Section XVI. Information based on data reported in CROWNWeb as of May, 2018. If missing, data were not available.

^[*2] Values are shown for the average facility.

[*3] Information based on CROWNWeb data as of March 2018. If missing, data were not available.

[*4] Values may not sum to exactly 100% because of unknown Medicare status.

^[*5] Data on this section are from the facility's latest survey since January 2009. If your facility has not been surveyed since January 2009, facility-level data on this table will be missing.